Sana Biotechnology

### Executive Summary Sana Biotechnology raised $828.2M in a private placement, with first sale on 2025-10-12. Backed by Lockheed Martin Ventures and Bessemer Venture Partners, this large capital raise signals strong conviction in synthetic biology and intracellular mRNA delivery. As a Regulation D filing, it remains a private offering. ### Investor Edge Monitor for subsequent Form D amendments (D/A) which could reveal additional investors or changes in terms. Also track any public announcements regarding partnerships or regulatory milestones that may precede a future IPO. ### Sector capital positioning This massive raise underscores growing institutional appetite for synthetic biology and mRNA delivery platforms, indicating a capital flow shift toward advanced biomanufacturing and therapeutic delivery systems. ### Convergence Signals No direct public signals (e.g., patents, contracts, legislation) are identifiable from the filing alone. However, Lockheed Martin Ventures' involvement suggests potential defense or aerospace applications of mRNA delivery technology. ### Key Takeaways - Massive $828.2M private placement in synthetic biology/mRNA delivery. - Blue-chip investors include Lockheed Martin Ventures and Bessemer Venture Partners. - First sale occurred 8 months ago; watch for amendments or public filing updates. ### Risk Indicators & Flags No red flags in initial Form D. However, the unusually large amount for a private placement warrants scrutiny of future D/A amendments or regulatory shifts in mRNA technology oversight. ### Verification & References All data from SEC Form D filing, accession number 0001702600-24-20343, available via EDGAR at https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany. Verify first sale date (2025-10-12) and related persons (Lockheed Martin Ventures, Bessemer Venture Partners) in the filing.